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Abstract
Background: Irritable bowel syndrome with diarrhoea (IBS-D) affects up to 4% of the general population. Symptoms
include frequent, loose, or watery stools with associated urgency, resulting in marked reduction of quality of life and
loss of work productivity. Ondansetron, a 5HT3 receptor antagonist, has had an excellent safety record for over 20 years
as an antiemetic, yet is not widely used in the treatment of IBS-D. It has, however, been shown to slow colonic transit
and in a small randomised, placebo-controlled, cross-over pilot study, benefited patients with IBS-D.
Methods: This trial is a phase III, parallel group, randomised, double-blind, multi-centre, placebo-controlled trial, with
embedded mechanistic studies. Participants (n = 400) meeting Rome IV criteria for IBS-D will be recruited from
outpatient and primary care clinics and by social media to receive either ondansetron (dose titrated up to 24mg daily)
or placebo for 12 weeks. Throughout the trial, participants will record their worst abdominal pain, worst urgency, stool
frequency, and stool consistency on a daily basis.
The primary endpoint is the proportion of “responders” in each group, using Food and Drug Administration (FDA)
recommendations. Secondary endpoints include pain intensity, stool consistency, frequency, and urgency. Mood and
quality of life will also be assessed.
Mechanistic assessments will include whole gut transit, faecal tryptase and faecal bile acid concentrations at baseline
and between weeks 8 and 11. A subgroup of participants will also undergo assessment of sensitivity (n = 80) using the
barostat, and/or high-resolution colonic manometry (n = 40) to assess motor patterns in the left colon and the impact
of ondansetron.
Discussion: The TRITON trial aims to assess the effect of ondansetron across multiple centres. By defining
ondansetron’s mechanisms of action we hope to better identify patients with IBS-D who are likely to respond.
Trial registration: ISRCTN, ISRCTN17508514, Registered on 2 October 2017.
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Background and rationale
Irritable bowel syndrome (IBS), which affects around
10% of the population, accounts for 1.8 million consul-
tations per year in primary care in England and Wales.
Around one third of these patients meet criteria for IBS
with diarrhoea (IBS-D). Symptoms include frequent,
loose, or watery stools with associated urgency, which
can severely limit socialising, travelling, and eating out.
This can lead to a marked reduction in quality of life
and loss of work productivity. When patients with IBS
are asked to rank symptoms in order of importance, er-
ratic bowel habit is rated first, followed by abdominal
pain and, for those with diarrhoea, urgency [1]. This
can often be associated with incontinence, which is so-
cially debilitating, but often under-reported [2].
Current treatments for patients with IBS-D such as
loperamide reduce bowel frequency, but do not improve
abdominal pain, and often lead to constipation. The lack
of effective treatments results in frequent referrals to
secondary care, and such patients represent a significant
proportion of gastroenterology outpatients.
A previous meta-analysis [3] showed that the 5-hy-
droxytryptamine-3 receptor antagonists (5HT3RAs) alo-
setron and cilansetron benefited such patients,
improving stool consistency, and reducing both fre-
quency and urgency of defaecation. However, these
drugs had serious side effects, including constipation in
25% of patients and, rarely, ischaemic colitis (1 in 700).
Alosetron was initially withdrawn and now is available
in the USA only, through risk evaluation and mitigation
strategy (REMS) and is not available in Europe. Cilanse-
tron never came to market, while ramosetron, another
5-HT3 receptor antagonist is only available in Japan
where it is licensed for IBS-D, with several good-quality
trials confirming its benefit [4, 5].
Ondansetron is a widely used 5HT3RA that, unlike
alosetron, has not been associated with ischaemic colitis.
A pilot randomised, placebo-controlled cross-over trial
showed that 5 weeks of ondansetron was effective in im-
proving diarrhoea and urgency [6]. Currently we do not
understand exactly how it works, nor can we predict the
individual dose required for optimum effect, which var-
ies widely. One key effect we found, also seen with other
5HT3RAs [7], was a marked reduction in urgency, which
may be important in improving quality of life in patients
with IBS-D [8].
Potential mechanisms of action of 5HT3 receptor
antagonists
The 5HT3RAs slow colonic transit, an effect we
found particularly marked in the left colon and the
rectosigmoid region of patients with IBS-D, but the
underlying mechanism was unclear [6]. Previous
studies of the impact of 5HT3RAs on human colonic
motility [9, 10] showed that the 5HT3RAs alosetron
and cilansetron increased peri-prandial frequency of
colonic contractions, and mean amplitude of con-
tractions in the left colon. We hypothesise that
5HT3RAs increase retrograde sigmoid motility, per-
haps enhancing “brake” function [11, 12], which
would be a novel mode of action. In our pilot study
we showed the decrease in urgency correlated dir-
ectly with the reduction in faecal protease [13], but
whether this represents a true causal relationship or
just an epiphenomenon is unclear. Faecal proteases
have been shown to be increased in IBS-D and, at
least in animal models, cause hypersensitivity to rec-
tal distension via activation of protease activated re-
ceptors type 2 (PAR2) [14]. We have shown that
most faecal proteases are endogenous [13], repre-
senting pancreatic enzymes that have escaped deg-
radation by colonic bacteria. We hypothesise that
slowing gut transit reduces faecal protease, by allow-
ing time for bacterial degradation, and that this may
also contribute to the beneficial effects of ondanse-
tron. This might also improve the anal soreness that
is commonly reported by patients with IBS-D. Bile
acids have also been shown to sensitise the rectum
[15], and elevated faecal bile acids have been identi-
fied by several groups in patients with IBS-D [16].
Slowing transit may increase the time for bile acid
deconjugation by colonic bacteria, and therefore en-
hance absorption, but how important this is in redu-
cing rectal sensitivity, compared with the effects on
faecal proteases, is unclear.
5HT3 receptor antagonist sensitivity
We have also shown that individuals vary widely in their re-
sponsiveness to ondansetron, explaining why trials using
fixed doses of 5HT3RAs result in severe constipation in
some patients. When patients were allowed to have dose ti-
tration we found that constipation was rare, occurring in
only 2% of patients. However, the required dose of ondan-
setron ranged from 4mg on alternate days to 8mg three
times a day (t.d.s.). The reasons for this variation are un-
clear but recent evidence suggests that responsiveness to
5HT3RAs might be linked to polymorphisms in the genes
controlling 5HT synthesis. Serotonin availability in the rec-
tal mucosa is thought to be determined by the activity of
the rate-limiting synthetic enzyme tryptophan hydroxylase-
1 (TPH-1), which produces serotonin in enterochromaffin
cells. A recent small study showed that TPH-1 mRNA
levels in rectal mucosa (and thus presumably serotonin syn-
thesis rate) were approximately doubled in responders to
another 5HT3RA, ramosetron, compared with non-re-
sponders, and that this was linked to the TPH-1 genotype
Gunn et al. Trials          (2019) 20:517 Page 2 of 12
[17]. TPH-1 rs211105 minor allele G was found in 44% of
non-responders, but only in 4% of responders, indicating
that possessing the major allele increases responsiveness to
the drug. It was also associated with worse diarrhoea, pos-
sibly because of the greater 5HT synthesis.
Investigational agent
Ondansetron is a potent, highly selective 5HT3RA,
which blocks 5HT3 receptors in the gastro-intestinal
tract and in the central nervous system. Ondansetron
is currently licenced for use in adults and children
for the management of nausea and vomiting induced
by cytotoxic chemotherapy and radiotherapy, and for
the prevention and treatment of post-operative nausea
and vomiting. Constipation is an unintended side ef-
fect of ondansetron, which was first shown to slow
colonic transit 30 years ago [18–20]. In our pilot
study, 120 patients were recruited to a randomised
double-blind, placebo-controlled, cross-over trial of
ondansetron treatment for IBS-D. Patients were ran-
domised to receive ondansetron (2 mg per day up to
8 mg t.d.s) followed by placebo or placebo followed
by ondansetron. Patients began on drug A for a
period of 5 weeks, then underwent a washout period
of 2–3 weeks, and then commenced drug B for 5
weeks. The primary outcome measure for the study
was the difference in average stool consistency in the
last 2 weeks of treatment of ondansetron versus pla-
cebo, and this showed a highly significant improve-
ment with active treatment. We also showed
significant benefits for both urgency and stool fre-
quency, with associated slowing of whole gut transit.
Despite having limitations, the results of this pilot
study were very encouraging, supporting our clinical
experience of the benefits of ondansetron.
Objectives
The primary objective is to determine the effectiveness and
safety of ondansetron in patients with symptoms of IBS-D,
including urgency, looseness of stool, frequency of defaeca-
tion, and abdominal pain. The trial also aims to understand
further the mode of action of ondansetron in these patients.
More specifically, we will examine the role of rectal sensi-
tivity and compliance, faecal bile acids and proteases, post-
prandial sigmoid motility, and genetic variation of serotonin
synthesis, both in terms of symptom generation in IBS-D
and in responsiveness to ondansetron. This will be achieved
by performing mechanistic studies within the clinical trial
to determine if changes in symptoms are correlated with
changes in these biomarkers.
Trial design
TRITON is a multi-site, parallel group, randomised,
double-blind, placebo-controlled trial with embedded
mechanistic studies within selected sites. Our aim is
to determine the superiority of ondansetron compared
with placebo. In total, 400 patients with IBS-D will be
randomised 1:1 to receive either ondansetron or pla-
cebo. Both treatments will be administered in oral
doses of between 4 mg every third day and 24 mg
daily for 12 weeks. Dose titration will be undertaken
in the first 2 weeks of the trial to avoid constipation,
which at a standard dose occurs in one quarter of pa-
tients. The primary outcome will be assessed over the
12 weeks post randomisation. Secondary and safety
outcomes will be measured up to 16 weeks following
randomisation. See Fig. 1 for an overview of the trial
procedures. The Standard Protocol Items: Recommen-
dations for Interventional Trials (SPIRIT) checklist is
provided as an Additional file 1.
Methods
Trial setting
This trial will be performed initially at 18 sites in the
UK. All sites will be required to recruit patients, per-
form all necessary protocol assessments, and offer pa-
tients the opportunity to take part in the whole-gut
transit assessment and the blood and stool collection.
In addition, four of the sites will perform the mech-
anistic assessments for the trial. Patients at all sites
will be offered an opportunity to take part in the
mechanistic studies but will be required to travel to
one of the specified sites for these assessments.
Eligibility criteria
Inclusion criteria
Patients must fulfil all of the following criteria:
 Meet Rome IV criteria for IBS-D (see Table 1)
 Age ≥ 18 years
 Have completed standardised workup to exclude
 Microscopic colitis (colonoscopy or flexible
sigmoidoscopy with colonic biopsies)
 Bile acid diarrhoea (selenium homocholic acid
taurine (SeHCAT) > 10%, C4 < 19 ng/ml or failed
to respond to 1 week trial of a bile acid binding
agent (colestyramine 4 g t.d.s., colesevelam 625
mg t.d.s. or equivalent))
 Lactose malabsorption (suggested but not
mandated negative lactose breath hydrogen
test, negative clinical challenge or failure to
respond to lactose-free diet)
 Coeliac disease (confirmed by tissue
transglutaminase (tTG) or duodenal biopsy)
 Patients of childbearing potential or with partners
of childbearing potential must agree to use
methods of medically acceptable forms of
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contraception during the trial and for 90 days
after completion of trial medication
 Women of childbearing potential must test negative
for pregnancy within 72 h of confirmation of
eligibility
 Weekly average worst pain score ≥ 30 on a 0–100-
point scale
 Stools with a consistency of 6 or 7 on the Bristol
Stool Form Score (BSFS) for 2 or more days per
week
Fig. 1 Schedule of enrolment, interventions and assessments throughout the TRITON study. 1 Date of birth, National Health Service (NHS)
number, address, telephone number (if consented to text messages), smoking history, height, weight. 2 White blood cell count (WBC), full blood
count (FBC), liver function tests (LFTs), urea and electrolytes (UEs), C-reactive protein (CRP). 3 Titrated to optimum dose during the first 2 weeks. 4
Recording worst abdominal pain (0–100), worst urgency (0–100), number of investigational medicinal product (IMP) taken, use of loperamide,
stool consistency of each stool passed, and relief from irritable bowel syndrome (IBS) symptoms at the end of each week. 5 Asking if they have
passed a stool type 6 or 7, and what their worst abdominal pain score was that day. 6 At baseline only, Physical Symptoms Questionnaire (PHQ)-
12; at baseline and visits, IBS Severity Scoring System (IBS-SSS), Short-form Leeds Dyspepsia Questionnaire (SF-LDQ), Hospital Anxiety and
Depression Scale (HADS), and IBS Quality of Life Questionnaire (IBS-QOL). 7 Six high-rectal biopsies taken either during mechanistic assessment or
at visit 3. 8 Whole blood (5 ml) at visit 3; serum (5 ml) at visits 3 and 5. 9 Four aliquots obtained and frozen at home prior to visit. 10 Performed at
University of Nottingham & QMUL only (n = 40); patients will receive additional payment for participation. 11 Performed at Nottingham/Leeds/
QMUL/UCL only (n = 80); patients will receive additional payment for participation
Gunn et al. Trials          (2019) 20:517 Page 4 of 12
Exclusion criteria
Patients must not fulfil any of the following criteria:
 Gastrectomy
 Intestinal resection;
 Other known organic gastrointestinal diseases
(e.g. inflammatory bowel disease (Crohn’s
disease, ulcerative colitis));
 Unable or unwilling to stop restricted medication
including regular loperamide, antispasmodics (e.g.
buscopan, mebeverine, peppermint oil, alverine
citrate), eluxadoline, tricyclic antidepressant
doses > 30 mg/day or other drugs likely in the
opinion of the investigator to alter bowel habit.
These medicines should be discontinued for a 7-
day washout period prior to registration;
 QTc interval ≥ 450 msec in men or ≥ 470 msec in
women (assessed within the last 3 months by
electrocardiogram (ECG));
 Previous use of ondansetron for chronic symptoms,
or contraindications to ondansetron;
 Pulse, blood pressure, laboratory-tested blood values
outside the normal ranges according to the site’s local
definition of normal (assessed within the last 3
months). Note minor rises in alanine
aminotransferase (ALT) (< 2 × upper limit of normal)
will be acceptable, but the patient’s General
Practitioner (GP) will be informed if ALT remains
elevated at the end of the trial;
 Women who are pregnant or breastfeeding;
 Patients currently or previously participating in a
trial of an investigational medicinal product (IMP)
in the previous 3 months, where the use of the
IMP may cause issues with the assessment of
causality in this trial;
 Patients who have started or who have had alterations
to their dosage of selective serotonin re-uptake
inhibitors or tricyclic antidepressants in the last 3
months, or who will have their dosage changed during
the trial;
 Patients currently taking and unwilling or unable to
stop taking apomorphine or tramadol (which
interact with ondansetron);
 Patients with only stools of consistency 7 on the
BSFS for 7 days a week.
Patients taking QT-prolonging or cardiotoxic drugs will
be reviewed by the local Principal Investigator (PI) to deter-
mine whether they are suitable for the trial.
Intervention
Eligible patients will be randomised in equal proportions
to receive either over-coated capsules of ondansetron 4
mg or over-coated placebo, for 12 weeks. The dose of
the IMP will be individually titrated during the first 2
weeks by calls from the research team on alternate days,
aiming for a stool consistency type 3–5 on the BSFS.
Adherence
Patients will receive face-to-face adherence reminders
on each trial visit, as well as the phone calls during the
2-week titration period. Any remaining IMP capsules are
counted at visits 4 and 5.
Dose titration
Since the optimum dose varies widely from 4mg on
alternate days up to 8 mg t.d.s., we will start all patients
on 4mg daily and after 2 days contact them to adjust the
dose, thus avoiding the complication of constipation. If
stool consistency remains loose, patients will be asked to
increase their dose in 4-mg steps every 2 days up to the
maximum of 8mg t.d.s. If stools become hard or there is
no bowel movement on day 2, they will be asked to stop
the drug for 1 day and recommence at a lower dose
changing from 4mg daily to 4 mg on alternate days. If
stools still remain hard or infrequent, patients will be
asked to reduce their dosage to 4 mg every third day. Pa-
tients will discontinue the trial in the unlikely event that
their stool remains hard even at this low dose.
Outcomes
Primary outcome measure
The primary outcome measure is to ascertain whether
12 weeks of ondansetron increases the FDA-defined re-
sponder rate (in relation to abnormal defaecation and
abdominal pain) compared with placebo. A responder is
a patient who records both a reduction in pain intensity
(≥ 30% decrease from baseline in weekly average worst
daily pain) and improvement in stool consistency (≥ 50%
decrease in the number of days per week with ≥ 1 loose
stool ((BSFS) [21] 6 or 7)) for at least 6 weeks of the 12-
week treatment period.
Secondary outcome measures
Secondary outcome measures will include:
Table 1 Rome IV diagnostic criteria for irritable bowel
syndrome with diarrhoea
Meet Rome IV criteria for IBS-D for the past 3 months:
- Recurrent abdominal pain at least weekly
- Pain is associated with two or more of the following; related to
defaecation, associated with a change in frequency of stool, associated
with a change in form of stool
- Symptoms onset at least 6 months prior to diagnosis
- Abnormal stools are loose (BSFS 6 or 7) in > 25% of cases but are hard
(BSFS 1 or 2) in < 25% of cases
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a) Stool consistency and abdominal pain (measured by
diary and daily text message);
b) Stool frequency, urgency of defaecation, and use of
rescue medication (defined as the use of
loperamide) over 12 weeks of treatment and the
answer to the question “Overall, have you had
satisfactory relief from your IBS symptoms in the
past week?” (measured by diary);
c) The following will also be assessed at the
beginning and the end of the trial: IBS symptom
severity (measured by the Irritable Bowel
Syndrome Severity Scoring System (IBS-SSS)
[22]), dyspepsia (using the Short Form Leeds
Dyspepsia Questionnaire (SF-LDQ) [23]), quality
of life and mood (using the Irritable Bowel
Syndrome Quality of Life (IBS-QOL) [24] and
Hospital Anxiety and Depression Scale (HADS)
[25] questionnaires), and somatic symptoms
(using the Patient Health Questionnaire 12
Somatic Symptoms (PHQ-12) [26]
questionnaire);
d) Stool frequency, stool consistency, urgency,
abdominal pain, and adverse events (AEs) assessed
4 weeks after the end of treatment to determine if
there are any persisting effects.
Mechanistic outcome measures
The trial will evaluate the possible mechanisms under-
lying any changes in the primary and secondary end-
points. The effect of ondansetron on whole gut transit
will be measured at baseline and 12 weeks (n = 400),
using radio-opaque markers and an abdominal x-ray as
previously described [27]. High-resolution manometry
will be performed at baseline and after 8–11 weeks of
treatment at two centres (n = 40) to assess whether
ondansetron decreases the number of high-amplitude
propagating contractions and increases the percentage
time occupied by cyclical retrograde propagated contrac-
tions [11]. Barostat assessment will be performed at
baseline and after 8–11 weeks of treatment at four
centres (n = 80, some of whom may also undergo man-
ometry), in order to assess if ondansetron increases rec-
tal compliance and decreases sensitivity (manifested as
increased pressure thresholds for pain and urgency).
Serum will be sampled to genotype patients for polymor-
phisms in the TPH1 gene (n = 400), and correlation
tested between these and the mucosal 5HT and TPH-1
mRNA obtained from high-rectal biopsies (n = 80), final
ondansetron dose, and responder status, to see whether
this predicts sensitivity and/or response to ondansetron.
Finally, stool sample analysis (n = 400) will be used to
assess whether ondansetron reduces total faecal bile acid
and tryptase concentrations, and correlation will be
tested between these and any changes in urgency.
Participant timeline
Visit 1
Potential trial candidates will attend their first visit for
registration and consent by the PI or delegate. If re-
quired, further tests to exclude diagnoses other than
IBS-D will be arranged. These include a SeHCAT scan,
serum C4 level, or a 1-week trial of a bile-acid binding
agent to assess for bile acid malabsorption (unless done
within the last 5 years), and colonoscopy (unless done
within 2 years, or 5 years if they also currently have nor-
mal calprotectin) to assess for microscopic colitis. Base-
line serum blood tests, vital signs, demographics (date of
birth, gender, ethnicity, and smoking history) and an
ECG will be obtained. Current medications will be
reviewed, and those unable to discontinue drugs likely to
alter bowel habit will be unable to enter the trial.
Patients on QT-prolonging drugs and cardiotoxic drugs
will be reviewed by the PI for suitability for the trial, as
ondansetron may increase the risk of QT prolongation
and arrhythmias. Eligible and consenting patients are
registered and allocated a unique trial ID and data col-
lected will be link anonymised.
All patients will be asked to complete a 2-week daily
diary recording stool frequency, the consistency of each
stool (using the BSFS), worst abdominal pain (on a scale
of 0–100), worst bowel movement urgency (on a scale
0–100), and if they have used loperamide that day. In
addition, patients have the option to be sent two auto-
mated text messages each day. The first will ask the
patient if they have passed a stool of consistency 6 or 7
on the BSFS. They will need to reply with either a yes or
no. The second text message will ask what their worst
abdominal pain score was that day. The patient must
respond with a number from a scale of 0–100 (where 0
is no pain and 100 is the worst imaginable pain).
Visit 2
The patient will return 2 weeks later to confirm eligi-
bility. The diary will confirm they have had stool
consistency BSFS 6–7 for more than 2 days a week
and do not have only BSFS 7 for 7 days per week,
and a weekly average worst pain score ≥ 30. Patients
who consent to the whole gut transit study will be
dispensed Transit-Pellet capsules containing markers,
and the abdominal x-ray appointment will be con-
firmed for the morning of visit 3. Patients will take
the Transit-Pellet capsules for 6 days prior to visit 3.
Patients who have consented to one or both mechan-
istic studies will have appointments arranged for base-
line assessment prior to visit 3.
Visit 3
On visit 3, patients will undergo a pregnancy test if
applicable, whole gut transit assessment by abdominal x-ray
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(if they have consented), rigid sigmoidoscopy (if they have
consented), completion of baseline questionnaire booklet
(including IBS-SSS, SF-LDQ, HADS, PHQ-12, and IBS-
QOL questionnaires), and collection of stool, whole blood,
and serum samples (if they have consented). Patients will
then be randomised and given a 6-week patient diary and
the trial medication in accordance with their blinded ran-
domisation allocation. Patients will be asked to record the
following on a daily basis: stool frequency, consistency of
each stool, worst abdominal pain experienced that day,
worst bowel movement urgency, number of trial medica-
tion capsules taken, and whether they have used lopera-
mide that day. Every week the diary will ask whether
they feel that they have had satisfactory relief from
their IBS symptoms that week. If they agree, the pa-
tient will continue to receive two text messages each
day for the next 6 weeks, asking if they have passed a
stool of a consistency of 6 or 7 that day, and what
their worst abdominal pain was that day.
During the first 2 weeks patients will be contacted
every 2 days by the local site team to discuss bowel habit.
The dose of ondansetron or placebo will then be titrated
as required. Additional guidance on dose titration will
be given to each trial site in a standard operating pro-
cedure, and to the patient in a dose titration instruction
leaflet. A check for serious adverse events (SAEs) will be
performed during each telephone call. The steady dose
to be taken forward for the remainder of the trial will be
confirmed in week 2, although this may be altered dur-
ing the 12 weeks if required, to avoid constipation.
Visit 4
Patients will return for their fourth visit at 6 weeks
of the trial treatment period. Diaries will be col-
lected, and the investigator will ask whether any re-
portable AEs have occurred since the last visit. A
pregnancy test will be taken and concurrent medica-
tions will be reviewed to ensure these do not inter-
fere with the trial medication. A further 6-week
patient diary, trial medication, and Transit-Pellet
capsules (for use 6 days prior to visit 5) will be dis-
pensed. Patients who have consented to mechanistic
studies will have appointments confirmed and these
will take place between 8 and 11 weeks of treatment.
Daily text messages will be sent for a further 6 weeks
to those patients who agree.
Visit 5
Patients will return for visit 5 after 12 weeks on the trial
medication. A pregnancy test will be taken, concurrent
medication will be reviewed to ensure that these do not
interfere with the trial medication, and the investigator
will ask whether any reportable AEs have occurred since
the last visit. Unused medication and completed patient
diaries will be collected. The abdominal x-ray to assess
whole gut transit will be performed in consenting pa-
tients. Serum and stool samples will be collected from
consenting patients, and all patients will complete the
12-week questionnaire booklet, including the IBS-SSS,
SF-LDQ, HADS, and IBS-QOL questionnaires. Patients
will be issued with a follow up diary and will continue to
respond to text messages for a further 4 weeks.
Visit 6
Patients will then return for the sixth and final visit,
where the diary will be collected and the investigator will
ask whether any reportable AEs have occurred since the
last visit.
Sample size
TRITON plans to recruit 400 patients from up to 24
sites across England and Scotland. This will provide 90%
power at 5% significance to detect a 15% absolute differ-
ence between the randomised groups in the proportion
of patients achieving the FDA-recommended [28] end-
point of a weekly response for pain intensity and stool
consistency for at least 6 weeks of the 12-week treatment
period. This difference (15%) is considered to represent
the minimum clinically important difference. We have
assumed a placebo response rate of 17%, as recently re-
ported using this endpoint and allowed for a 15% attri-
tion rate.
Whole gut transit
Our previous study using the same radio-opaque marker
technique as we propose to use showed ondansetron in-
creased whole gut transit time by a mean (95% CI) of 10
(6–14) h. Using 200 patients per group gives 90% power
to detect a change of 0.7 h. The larger numbers will also
give us the power to test correlation with other endpoints.
High-resolution left-sided colonic manometry
Previous studies with the closely related 5HT3RA alose-
tron showed an increase in motility index compared
with placebo, with a mean (standard deviation (SD)) of
1.0 (1.2) [29], indicating we would have 80% power to
detect a standardised effect size of 1 with 17 patients.
We will aim for 20 patients on each treatment to allow
for dropouts i.e. 40 each undergoing two studies, a total
of 80 high-resolution manometry (HRM) studies.
Rectal compliance and sensitivity
Previous studies [29] with alosetron showed an increase
in compliance from 5.9 (SD 1.3) to 9.8 (SD 1.2) ml/
mmHg in 22 patients. We propose to study more pa-
tients to test correlation with symptoms, which typically
requires much larger numbers, so we will aim to study
40 patients on each treatment.
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Recruitment
Patients with IBS-D will be identified at recruiting sites
from outpatient clinics and lists of patients that have
previously consented to be contacted for information on
upcoming research studies by local investigators and re-
search nurses. Potentially eligible patients with IBS-D
will also be identified by primary care general practices
and local pharmacies, working either as patient identifi-
cation centres (PIC), or a source of trial advertising. The
TRITON trial will also be advertised using posters and
leaflets in electronic and paper form and distributed to
relevant locations outside of the secondary care setting
and will advise patients to visit the trial website for fur-
ther information. Patients will be screened against the
aforementioned inclusion and exclusion criteria and will
be provided with trial information.
Randomisation
Randomisation will be performed on a 1:1 basis to re-
ceive either ondansetron or placebo, and each patient
will be allocated three bottles of trial medication, each
with a unique IMP kit code. Minimisation will be used,
in order to ensure treatment groups are well-balanced.
The stratification factors are registering site and whether
the patient has undergone mechanistic assessments.
Blinding
As the trial is double-blind, neither the patient nor those
responsible for their care and evaluation (treating team
and research team) will know the allocation or coding of
the treatment allocation. This will be achieved by identi-
cal packaging and labelling of both the over-encapsu-
lated ondansetron and matched placebo. Each bottle of
ondansetron/placebo will be identified by a unique kit
code. Randomisation lists containing kit allocation will
be generated by the safety statistician at the Clinical Tri-
als Research Unit (CTRU) and sent to the clinical supply
company, which will produce the kits and the code-
break envelopes. Management of kit codes on the kit lo-
gistics application, which is linked to the 24-h random-
isation system, will be conducted by the CTRU safety
statistician in addition to maintaining the back-up kit-
code lists for each site.
Access to the code break envelopes will be restricted
to the safety statistician and designated safety team.
Code breaks will be permitted in emergency situations,
where treatment allocation knowledge is needed to opti-
mise treatment of the patient. Any unblinded interim
reports provided to the Data Monitoring and Ethics
Committee (DMEC) will be provided by the CTRU




Responders According to the FDA definition [28], a
responder is a patient who records both a reduction in
pain intensity (≥ 30% decrease from baseline in weekly
average worst daily pain) and improvement in stool
consistency (≥ 50% decrease in the number of days per
week with ≥ 1 loose stool of BSFS [21] 6 or 7) for at least
6 weeks of the 12-week treatment period, which is re-
corded in the daily diary and text messages.
Secondary outcome methods
Daily diary entries will record stool consistency, worst
abdominal pain, stool frequency, worst urgency of
defaecation, use of rescue medication over 12 weeks
of treatment, and the answer to the question “Overall,
have you had satisfactory relief from your IBS symp-
toms in the past week?”. The same diaries will be
used between visits 5 and 6 to determine if there are
any persisting effects of the treatment. Questionnaire
booklets at visits 3 and 5 will record IBS-SSS, SF-
LDQ, IBS-QOL, and HADS.
Mechanistic outcome methods
Whole gut transit (n = 400) will be assessed at visits 3
and visit 5 by ingestion of radio-opaque markers 6
days before an abdominal x-ray, as previously de-
scribed [27]. Serum will be sampled (n = 400) at visit
3 to genotype patients for polymorphisms in the
TPH1 gene. Stool samples (n = 400) will be collected
and frozen by patients in their homes prior to ran-
domisation and at visit 5 to assess for total faecal bile
acid and tryptase concentrations.
High-resolution manometry (n = 40) will be performed
prior to randomisation and between 8 and 11 weeks of
treatment, at two centres. Patients will fast overnight,
then receive a tap water enema at 37 °C prior to endo-
scopically siting the manometry catheter, which is
clipped to the mucosa of the splenic flexure. After 30
min of rest, the manometer will start recording for 4 h.
At 2 h the patient will be given a meal to stimulate co-
lonic contractions.
Barostat assessment (n = 80) will be performed prior to
randomisation and between 8 and 11weeks of treatment,
at four centres. Patients will fast overnight, then receive a
tap water enema at 37 °C prior to digital insertion of a
barostat rectal compliance balloon. The bed will be tilted
15° head down to reduce abdominal visceral pressure on
the rectum. After calibration the balloon will be inflated in
increments of increased pressures, during which time pa-
tients will respond with their corresponding sensation of
no sensation, first sensation, desire to defecate, urgency,
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discomfort, or pain. If the sensation of pain is reached the
balloon is immediately deflated.
Six high-rectal biopsies will be obtained per patient
(n = 80) either by endoscopy after siting of the colonic
manometer or via rigid sigmoidoscopy after barostat
assessment or at visit 3. Four biopsies will be snap-
frozen and two will be placed in RNA later prior to
freezing at − 80 °C before being analysed for mucosal
5HT and TPH-1 mRNA.
Data analysis
General considerations
All hypothesis tests will be two-sided with a 5% sig-
nificance level. Methods to handle missing data are
described for each analysis. Analysis and reporting
will be in line with Consolidated Standards of Report-
ing Trials (CONSORT) [30]. As TRITON is a double-
blind trial, the trial statistician will be blinded to
treatment group allocation throughout the trial, until
the database has been locked and downloaded for
final analysis. Only the safety statistician, supervising
trial statistician, back-up safety statistician, and
authorised unblinded individuals at the CTRU will
have access to unblinded treatment group allocation
prior to final analysis.
Frequency of analyses
Outcome data will be analysed once only at the final
analysis, although statistical monitoring of safety data
will be conducted throughout the trial and reported
at agreed intervals to the DMEC. Final analysis will
take place 16 weeks after the last patient is
randomised.
Endpoint analysis
All analyses will be conducted on the intention-to-
treat population, defined as all patients randomised
regardless of non-compliance with the intervention.
The primary endpoint will be analysed per-protocol
to indicate whether results are sensitive to the exclu-
sion of patients who violated the protocol (e.g. those
patients randomised but subsequently found to be in-
eligible). Primary and secondary analysis will be per-
formed blinded to random allocation. Outcome
measures will be analysed by regression models ap-
propriate to the data type. Such analyses will be ad-
justed for randomisation minimisation factors: site,
completion of manometry assessment, barostat assess-
ment, and baseline values where applicable, age, and
gender. Baseline characteristics will be summarised by
randomised group.
Primary analysis
The primary analysis will compare the difference be-
tween treatment groups in the proportion of patients
achieving the FDA-recommended endpoint at 12 weeks
post-randomisation, using a logistic regression model
adjusted for minimisation, age, and gender. Any missing
data will be assumed missing at random (MAR) and im-
puted for the primary analysis. Odds ratios and corre-
sponding 95% confidence intervals will be presented.
Sensitivity will be analysed to assess the impact of
missing data on the treatment effect. This will include
complete case analysis and alternatives to multiple
imputation (e.g. pattern mixture modelling) if missing
patterns suggest data are missing not at random.
Secondary analyses
The difference between the treatment groups in the
proportions of patients with satisfactory relief of IBS
symptoms at 12 weeks post-randomisation will be ana-
lysed using logistic regression models, adjusting for
minimisation, baseline values, age, and gender. Odds
ratios and corresponding 95% confidence intervals will
be presented. Any missing data will be assumed MAR
and imputed.
The differences between the two treatment groups in the
continuous secondary endpoints at 12 weeks post-random-
isation will be analysed using linear regression models, ad-
justed for the minimisation variables, baseline values where
applicable, age, and gender. These endpoints are urgency of
defaecation over the last month, stool frequency over the
last month, number of days per week with at least one loose
stool (BSFS > 5) over the last month, average stool
consistency, number of days rescue medication used over
12 weeks, abdominal pain score, HADS depression and
anxiety scores, SF-LDQ score, IBS-QOL score and sub-
scales, and PHQ-12 and IBS-SSS severity scores. Treatment
estimates and corresponding 95% confidence intervals will
be reported. Any missing data will be assumed MAR.
The differences between the treatment groups in stool
frequency, abdominal pain, and urgency of defaecation
post-treatment, over weeks 13–16 post-randomisation, will
be analysed using a linear regression model adjusted for
minimisation factors, baseline values, and relevant baseline
factors. Treatment estimates and corresponding 95% confi-
dence intervals will be reported. Any missing data will be
assumed MAR.
Exploratory analyses on the daily measurements (worst
abdominal pain, loose stools, number of stools passed,
consistency of stool, worst urgency, and use of loperamide)
will be carried out using repeated measures models, which
incorporate correlation between measurements from the
same patient. SAS software version 9.4 will be used in the
analyses of primary and secondary endpoints.
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Safety analyses
All patients who receive at least one dose of trial
treatment will be included in the safety analysis set.
The number of patients reporting a SAE (up to 28
days after the last dose of treatment) and details of
all SAEs will be reported for each treatment group.
The number of patients withdrawing from trial treat-
ment will be summarised by treatment arm, along
with reasons for withdrawal. All safety analyses per-
formed prior to final analysis will be undertaken by
the safety statistician (rather than the trial statisti-
cian), thus ensuring that the trial team remain
blinded.
Subgroup analyses
No subgroup analyses are planned.
Mechanistic studies
Mechanistic studies will be analysed blinded to the inter-
vention allocation, by the site research fellow under super-
vision of the Chief investigator and local supervising PIs.
The differences between treatment groups in changes in
whole gut transit times, colonic motility measures (per-
cent time of cyclical retrograde contractions and high-
amplitude propagating contraction (HAPC) frequency),
rectal compliance, and thresholds for urgency and pain
measured using the barostat, faecal bile acid concentra-
tions, and faecal tryptase will each be assessed by linear re-
gression models. In addition, exploratory mediator
analyses will explore whether treatment effects, in terms
of changes in urgency or pain, are mediated through
changes in faecal bile acids or protease. Exploratory sub-
group analysis (tests of interactions) will be performed to
investigate the effect of the presence of each specified sin-
gle nucleotide polymorphism allele on response to treat-
ment, using logistic regression with addition of an
interaction term for the allele and treatment.
Adverse events
An AE is any untoward medical occurrence (including
deterioration of a pre-existing medical condition) in a
patient or clinical trial patient administered a medicinal
product, and which does not necessarily have a causal
relationship with this product. The occurrence of report-
able AEs will be recorded at visits 4, 5, and 6. At each
visit the research nurse will complete the AE checklist to
determine if the patient has suffered with any of the ex-
pected AEs. Only the confirmation of occurrence and
corresponding severity will be recorded.
Committees
Trial Management Group
A Trial Management Group (TMG) will be convened in-
cluding the Chief Investigator, co-investigators and
identified key collaborators, the trial statistician, and trial
manager. Notwithstanding the legal obligations of the
Sponsor and Chief Investigator, the TMG will have op-
erational responsibility for the conduct of the trial. The
TMG will meet quarterly as a minimum, and will be
responsible for protocol completion, case report form
(CRF) development, and monitoring of screening, re-
cruitment, treatment, and follow-up procedures.
Data Monitoring and Ethics Committee
A DMEC will be convened to monitor data collected
during the trial and make recommendations to the Trial
Steering Committee (TSC) on whether there are any
ethical or safety reasons as to why the trial should not
continue. It will consist of an independent Chair, an in-
dependent statistician, and an independent clinician.
Trial Steering Committee
A TSC will be convened with an independent majority.
Participants will include as a minimum, an independent
Chair, an independent statistician, an independent clin-
ician, a patient and public involvement (PPI) representa-
tive, the Chief Investigator, the Sponsor’s representative,
and other members of the TMG as required to update
on trial progress. The role of the TSC will be to provide
overall supervision of the trial progress and advice on
operational issues as necessary to the TMG. The TSC
will meet annually as a minimum.
Discussion
Our pilot study has shown that ondansetron provides an
opportunity to help patients with IBS-D, not only with
diarrhoea, but also with urgency, frequency of defecation,
and bloating. When patients with IBS-D are asked about
their concerns, erratic unpredictable bowel habit and ur-
gency in particular, are rated as having the greatest impact
on quality of life, so improvement in urgency and stool
frequency may be of considerable value. However, abdom-
inal pain is a key part of IBS, so we have used the com-
bined FDA-recommended outcome measure, which
includes both reduction in pain and improvement of diar-
rhoea as our primary endpoint, rather than just stool
consistency, as in the pilot.
This larger clinical trial aims to confirm the effectiveness
of ondansetron in managing IBS-D and, by mechanistic
assessments, shed light on both the pathophysiology of
the condition and the mode of action of ondansetron in
this population. With greater understanding of the condi-
tion, we hope this will allow the design of better treat-
ments in the future.
Current alternatives to 5HT3RA include loperamide
and the recently introduced eluxadoline. There are
only a few very small trials of loperamide in IBS-D,
which clearly show its effectiveness in controlling
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diarrhoea but not pain [31, 32]. Anecdotally, patients
often report constipation following loperamide use,
and this is associated with bloating and discomfort.
Eluxadoline is a combined μ-opioid agonist and δ-opi-
oid antagonist shown to increase the proportion of re-
sponders from 5.7% on placebo to 11–13.8% in a dose-
response study [33]. However, the main effect was on
stool consistency with no obvious effect on pain. Un-
fortunately, this drug has been associated with acute
pancreatitis, which is an unacceptable side effect for
most patients with IBS so the search for alternative
safe treatments remains important.
If ondansetron is effective in our trial, it could eas-
ily be widely adopted since it is an inexpensive, safe,
and generic drug. By providing an effective treat-
ment, it could not only reduce patient symptoms,
but also reduce healthcare costs associated with re-
peated referral and unnecessary investigations.
Protocol version
Protocol version 6.0, 6 November 2018 amended 5 De-
cember 2018. Recruitment opened on 19 March 2018,
expected completion December 2021.
Additional file
Additional file 1: SPIRIT 2013 checklist. (DOCX 62 kb)
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